Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 3/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.59 |
| ▸ | KISS1R | Q969F8 | 4/20 | 0.58 |
| ▸ | ERAP2 | Q6P179 | 3/20 | 0.56 |
| ▸ | IL1RN | P18510 | 2/20 | 0.56 |
| ▸ | NPY1R | P25929 | 3/20 | 0.55 |
| ▸ | NPY2R | P49146 | 3/20 | 0.55 |
| ▸ | NPY4R | P50391 | 3/20 | 0.55 |
| ▸ | CCKBR | P32239 | 3/20 | 0.54 |
| ▸ | CCKAR | P32238 | 1/20 | 0.54 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30180814 | 0.93 | OPRD1 (0.63) | OPRD1OPRM1KISS1RERAP2IL1RN | |
| SCHEMBL30180772 | 0.89 | OPRD1 (0.59) | OPRD1OPRM1KISS1RERAP2IL1RN | |
| SCHEMBL30823996 | 0.89 | KISS1R (0.60) | OPRD1OPRM1KISS1RERAP2IL1RN | |
| SCHEMBL30567421 | 0.88 | ERAP2 (0.62) | OPRD1OPRM1ERAP2IL1RNNPY1R | |
| SCHEMBL31303497 | 0.87 | ERAP2 (0.61) | OPRD1OPRM1ERAP2IL1RNNPY1R | |
| SCHEMBL31303469 | 0.87 | ERAP2 (0.61) | OPRD1OPRM1ERAP2IL1RNNPY1R | |
| SCHEMBL30772212 | 0.85 | ERAP2 (0.64) | OPRD1OPRM1ERAP2IL1RNERAP1 | |
| SCHEMBL31276131 | 0.85 | ERAP2 (0.59) | OPRD1OPRM1KISS1RERAP2IL1RN | |
| SCHEMBL30054135 | 0.85 | EDNRA (0.58) | OPRD1OPRM1ERAP2IL1RNCCKBR | |
| SCHEMBL31064875 | 0.85 | KISS1R (0.55) | KISS1RERAP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230046728-A1 | TECHNOLOGIES USEFUL FOR ASSESSING PERMEABILITY | PARABILIS MEDICINES, INC. | 2023-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230046728-A1 | TECHNOLOGIES USEFUL FOR ASSESSING PERMEABILITY | SLC47A2, EPCAM, SLC47A1 | OPRD1 2406/4885OPRM1 2322/4885KISS1R 3400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.